HPTN 084: Long-Acting Injectable Cabotegravir Superior to Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

January 27-28 and February 3-4, 2021
Monthly cabotegravir injections were associated with an 89% lower risk of HIV infection vs daily oral TDF/FTC; both strategies were generally safe and well tolerated, with no discontinuations for injection-site reactions.
Format: Microsoft PowerPoint (.ppt)
File Size: 220 KB
Released: January 30, 2021


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment

Dr. Zhao Yan Released: April 19, 2021

Clinical Care Options (CCO) commentary by Nelly Mugo, MD, on new data from Kenya on STI incidence and on PrEP uptake from CROI 2021

Nelly Mugo, MBChB, MMed, MPH Released: April 15, 2021

CCO expert commentary by Dr Monica Gandhi on key considerations with long-acting pre-exposure prophylaxis based on data presented at CROI 2021

Monica Gandhi, MD, MPH Released: April 8, 2021

Expert selections of important HIV data from CROI 2021, including current and investigational ART and ART in pregnancy and postpartum period, from CCO

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: March 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.